The $2.4B Oral Macrocycle and Bispecific Surge: Why Big Pharma Is Buying Platform Engines Over Single Assets
Dr. Dereck Mush, MD, MBA
What they do
Excelra announced on November 10, 2026 that its GOSTAR data supports Boltz's AI models for drug discovery. The collaboration supplies curated bioactivity and solubility information used across Boltz's modeling work. Gabriele Corso is co-founder and CEO of Boltz PBC. This is a research data collaboration, not an announced clinical result or financing round.
People in this update
- Gabriele CorsoCo-founder and CEOSource
The record
- Vertical
- Biotech & Drug Discovery
- Sub-segment
- AI molecular modeling
- Product type
- Platform software
- Stage
- Headquarters
- Not disclosed
- Region
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Biotech & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA
Molecular Cardioprotection: How Pediatric Myosin Inhibition Redefines the Economics of Congenital Heart Care
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA